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postpartum placement
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Background: Insertion of levonorgestrel-releasing intrauterine system (LNG-IUS) at caesarean section (CS) provides
contraception prior to resumption of ovulation or sexual activity. Patient satisfaction with insertion at CS has not
previously been studied.
Aims: The aim of this study was to compare patient satisfaction with LNG-IUS inserted at the time of lower uterine
segment CS to six weeks postpartum.
Materials and Methods: Open-label randomised controlled trial. Women booked for elective CS were randomised to
LNG-IUS insertion either at the time of CS (study group) or at six weeks postpartum (control group). The primary
outcome measure was patient satisfaction. Outcomes were measured at six weeks, three months and six months
postpartum.
Results: Forty-eight women were randomised into two treatment groups. Twenty-five women were randomised to have
LNG-IUS inserted at the time of CS, 23 of whom had the planned intervention and two had the LNG-IUS inserted
postpartum. Twenty-three women were randomised to the control group, four of whom withdrew prior to treatment. The 44
remaining women contributed to data analysis. Patient satisfaction was high and similar in both groups. At six months
postpartum, 90.5% of the study group were very satisfied or somewhat satisfied compared with 88.2% of the control group.
Conclusions: Patient satisfaction is high with LNG-IUS insertion at CS and not different to that with delayed insertion.
LNG-IUS insertion may be an option for women who find postpartum contraception difficult to access.
Key words: caesarean section, intrauterine devices, medicated, levonorgestrel-releasing intrauterine system, patient
satisfaction, postpartum period.
Introduction
The levonorgestrel intrauterine system (LNG-IUS
Mirena; Bayer Healthcare) provides long-acting
reversible contraception with satisfaction rates over 90%.1
Insertion of LNG-IUS at the time of caesarean section
(CS) provides immediate long-acting reversible
contraception with several advantages over device insertion
at the usual time of six to eight weeks postpartum
(postpueperal or delayed insertion). These advantages
include convenience, high patient motivation and
immediate contraception prior to resumption of
ovulation.2,3 Uptake may also be higher with insertion at
the time of delivery, as two studies of LNG-IUS insertion
at the time of CS4 and vaginal delivery5 both found that
the women in the delayed insertion group were less likely
to have the device inserted. Another benefit of insertion at
CS is that women who have LNG-IUS inserted at CS also
have less bleeding postpartum than women who have a
copper-containing intrauterine contraceptive device
(IUCD) inserted or no IUCD inserted at the time of CS.6
Despite the possible advantages of insertion of LNG-
IUS at CS, the procedure is not commonly done in
Australia, perhaps due to concerns about the safety of the
procedure, visibility of strings and risk of expulsion.
There is reassuring evidence that insertion of an IUCD
at the time of CS does not increase the risk of infection or
perforation,2,7 whereas insertion in lactating women is
associated with increased risk of uterine perforation.8
Rates of visibility of the LNG-IUS or IUCD strings in
the vagina depend on the technique of insertion at CS.
Strings are visible in the vagina in only 25% of women
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when the strings are not directed through the cervix;9
however, directing the strings through the cervix increases
the chance of visibility at follow-up to 92%,10 and
elongating the strings and threading them through the
cervix using the insertion tubing increase string visibility to
100%.11
Expulsion rates of various IUCDs inserted at the time
of CS generally seem to be higher than after delayed
insertion, with expulsion rates of 0–10.9% at six months
following IUCD insertion at CS,7,10–13 compared with
3–5% following delayed insertion.14,15 Less data exist for
expulsion of LNG-IUS inserted at CS, and expulsion
rates may be device specific. Reported rates of expulsion
of LNG-IUS inserted at CS range from 09 to 20%.4
Another issue with immediate insertion of LNG-IUS at
CS is the possible effect of progestogen on the infant via the
breast milk. There is no evidence that the use of
progestogen-containing contraceptives affects the quantity
or quality of breast milk and they appear to have no
deleterious effects on infant health.16,17 Despite this, the
2010 WHO medical eligibility criteria categorised
progestogen-containing contraceptives as medical eligibility
criteria category 3 (the theoretical or proven risks usually
outweigh the advantages of the method) in the first four
postpartum weeks in breastfeeding women, due to lack of
data on possible long-term health effects of neonatal
exposure to progestogens.17,18
There is a paucity of data on insertion of LNG-IUS at
CS. Randomised controlled trials of LNG-IUS insertion at
CS have assessed usage at one year (compared to LNG-
IUS insertion six to eight weeks postpartum4) and bleeding
patterns (compared to copper-containing IUCD inserted at
CS or no device inserted at CS6). No studies have
specifically examined uptake rates or patient satisfaction
with LNG-IUS inserted at CS,3 and large studies are
required to look at effectiveness and device expulsion.
A randomised controlled clinical study was conducted
to assess and compare patient satisfaction after six months
in women with LNG-IUS inserted at the time of CS
(study group) with those who had LNG-IUS inserted six
weeks postpartum (control group). We also collected data
on some safety aspects (pelvic infection and uterine
perforation), visibility of strings in the vagina, device
position within the uterine cavity, expulsion, vaginal
bleeding, breastfeeding rates and infant weight gain.
Materials and Methods
All consecutive women who were planning to have an
elective CS at Mackay Base Hospital in regional North
Queensland between 1 January 2011 and 31 December
2012 were invited to take part in the study in the antenatal
clinic. The only exclusion criteria were prolonged rupture
of membranes, suspected chorioamnionitis, uterine
anomalies, cervical dysplasia, age under 18 years and
inability to give informed consent.
After informed consent was obtained, women were
randomised to have the LNG-IUS inserted at the time of
CS (study group) or at the usual time six weeks later
(control group). Randomisation was done in blocks of 10
using a computer-generated list. Allocation forms were in
sequentially numbered sealed opaque envelopes.
The nature of the intervention made blinding
impossible; thus, the study was conducted as open label,
with both patients and clinicians aware of the treatment
allocation.
LNG-IUS insertion in the experimental group was
performed using the technique described by Puzey,9 the
only published method identified at the time of the study.
The LNG-IUS was inserted by an obstetrician or an
obstetric registrar experienced in the normal method of
insertion of the LNG-IUS. The device was inserted
through the uterine incision to the fundus of the uterus
using the normal applicator. The strings were cut at the
level of the uterine incision and gently pushed up against
the posterior wall of the uterus, and not pushed through
the cervix. The device was not sutured into the cavity, and
the uterine muscle closure was performed as per normal
practice. All women had prophylactic antibiotics at the
time of CS as per normal practice. LNG-IUS insertion in
the control group was performed in the usual way by an
experienced obstetrician or obstetric registrar.
Follow-up visits were performed by doctors in the
women’s health clinic six weeks, three months and six
months after delivery. At each follow-up visit, women
were asked to rate their satisfaction with LNG-IUS on a
five-point scale (ranging from very dissatisfied to very
satisfied). They were also asked about breastfeeding
behaviour and difficulties, and recent bleeding pattern. At
each visit speculum, vaginal and pelvic ultrasound
examinations were performed and baby weights were
recorded. As per the study protocol, LNG-IUS that were
low or oblique within the uterine cavity were removed and
a replacement LNG-IUS offered.
The primary outcome was patient satisfaction at six
months postpartum. Secondary outcomes were safety
aspects (pelvic infection and perforation), string visibility,
correct device position (including expulsion), vaginal
bleeding, breastfeeding, breastfeeding difficulties and
infant weight gain.
Sample size calculations revealed that a sample size of
16 (in each group) provided power in excess of 80% to
detect a difference of 0.5 on the satisfaction scale (the
smallest difference deemed clinically relevant) from the
expected mean in the control group of 4.5 (with a
standard deviation of 0.5) as significant at an alpha level
of 5%. The targeted initial sample size was increased to 25
women per group to account for patient attrition (such as
loss to follow-up).
All statistical analyses follow the intention-to-treat
principle. Descriptive statistics were based on percentages
(categorical variables) or mean (SD)/median (interquartile
range), depending on normality assumptions of the
underlying numerical variables.
Bivariate tests for categorical variables between the
groups were conducted using exact binomial tests
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(standard for nominal variables; trend tests for ordinal
variables). Bivariate tests for numerical variables employed
were t-tests when normality assumptions held or exact
versions of Wilcoxon tests otherwise.
The main outcome (dichotomised to positive/indifferent
or negative responses) was also checked by multivariate
logistic regression modelling for potential confounding.
Crude and adjusted odds ratios, together with their 95%
confidence limits, were calculated.
All statistical analyses were conducted using STATA
version 12 (StataCorp LP, College Station, TX, USA) at
a P-level of 5%.
Results
Forty-eight women were recruited to the study and
randomised. Twenty-five women were randomised to
have LNG-IUS inserted at CS (study group). Twenty-
three of these women had the planned intervention; two
women did not have the LNG-IUS inserted at the time
of CS because the device was forgotten or not available
at the time of surgery. Both of these women had it
inserted six weeks postpartum and were analysed with
the study group according to intention-to-treat
principles. Twenty-three women were randomised to
have the LNG-IUS inserted at the usual time six weeks
postpartum (control group). Four of these women
withdrew from the study prior to treatment and were
excluded from the statistical analysis. Of the 44 women
remaining in the trial, 100% attended at least one
follow-up visit, 41 (93%) attended at least two follow-up
visits, and 37 (84%) of women attended all three follow-
up visits.
Table 1 displays the demographic data of the women in
the two randomised groups. Since patients in the control
group were slightly younger, additional multivariate checks
for potential confounding were conducted with respect to
the main outcome (see below).
Patient satisfaction at six months was the primary
outcome. Satisfaction at six months (and during the whole
of the follow-up period) was not significantly different
between the two groups. At six months, 90.5% (19/21) in
the study group were very or somewhat satisfied,
compared with 88.2% (15/17) in the control group
(P > 0.99). The mean satisfaction rating at six months
was 4.52/5 for the study group and 4.47/5 for the control
group (P = 0.87; Table 2). The alternative hypothesis that
satisfaction in the study group differs by at least 0.5 points
on the assessed scale when compared with the control
group thus is rejected. Adjusting for potential confounders
(age, marital status, ethnicity, parity and number of prior
vaginal deliveries) validates the above-stated bivariate
findings with no significant results for the treatment effect
in the adjusted model (P = 0.90), thus disproving any
relevant confounding originating from the assessed
variables.
There were no pelvic infections or uterine perforations
due to insertion of LNG-IUS in either group.
LNG-IUS strings were significantly more likely to be
visible in the control group compared with the
experimental group at six months (82.4% versus 31.6%,
P = 0.03; Table 3).
There were no cases of LNG-IUS expulsion during the
study although two LNG-IUS inserted at CS were
subsequently found to be low or oblique within the uterine
cavity on ultrasound examination, and two inserted
postpartum were initially correctly positioned but found to
be low in the uterine cavity on follow-up ultrasound
examination (Table 3). According to the study protocol,
these were removed. Three women had new devices
inserted, and one woman whose LNG-IUS had been
inserted six weeks postpartum declined insertion of a
second device at six months postpartum. Neither of the
two women who had LNG-IUS inserted at CS and
subsequently found to be low or oblique within the uterine
cavity had strings visible in the vagina. One of these
women had her device removed easily using an Emmett
thread retriever, and the other woman had her device
changed under general anaesthesia.
Frequent vaginal bleeding was more common at six-
week follow-up in the study group (50% versus 10.5%,
P = 0.009) but not statistically different at three months or
six months (Table 3).
Rates of breastfeeding were consistently higher in the
group who had LNG-IUS inserted at the time of CS
(52.4% versus 11.8% at six months postpartum,
P = 0.015). Rates of difficulty with breastfeeding were low
and not different between the two groups. There was no
Table 1 Baseline characteristics of the study population
LNG-IUS
postpartum
(n = 19)
LNG-IUS
at caesarean
(n = 25) P-value
Age (mean (SD), years) 28.4 (4.8) 31.0 (4.9) 0.08
Ethnicity, % (n)
White 89.5 (17) 84.0 (21) 0.68
Aboriginal/Torres
Strait
10.6 (2) 4.0 (1)
Other 0 12.0 (3)
Marital status, % (n)
Married 63.2 (12) 72.0 (18) 0.75
De facto 36.8 (7) 24.0 (6)
Separated 0 4.0 (1)
Parity, % (n)
1 5.3 (1) 8.0 (2) 0.80
2 52.6 (10) 40.0 (10)
3 or more 42.1 (8) 52.0 (13)
No of vaginal
deliveries, % (n)
0 84.2 (16) 88.0 (22) >0.99
1 10.5 (2) 8.0 (2)
2 or more 5.3 (1) 4.0 (1)
Infant birth weight
(mean (SD), g)
3553 (665) 3673 (605) 0.53
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significant difference in infant weight gain between the two
groups (Table 4).
Discussion
Insertion of LNG-IUS at the time of CS provides long-
acting reversible contraception prior to resumption of
ovulation and avoids the need for insertion six to eight
weeks postpartum. There have been no large or long-term
randomised controlled trials of LNG-IUS insertion at CS.
This is the first study designed to assess patient
satisfaction with insertion of LNG-IUS at CS compared
to postpartum insertion. High follow-up was achieved with
all women attending at least one follow-up visit. Analysis
of the two groups by intention-to-treat principle showed
that patient satisfaction with insertion of LNG-IUS at the
time of CS was high and not different to satisfaction with
insertion six weeks after delivery.
One finding of note is that all women randomised to
have a LNG-IUS inserted at CS had the device inserted
(though two insertions were performed six weeks
postpartum). The four women who withdrew from the
study had all been randomised to have LNG-IUS inserted
postpartum. This finding is similar to the findings from
other studies that women are less likely to have LNG-IUS
inserted four to eight weeks postpartum than at the time
of CS4 or vaginal delivery.5 It is plausible that women are
less likely to attend to have LNG-IUS inserted six weeks
postpartum due to difficulty or inconvenience of accessing
postpartum care, or fear of an outpatient procedure.
One problem with LNG-IUS insertion at CS was that
the strings were visible in the vagina of in only 31.6% of
women. This low rate was due to the insertion technique
chosen, and modification of the insertion technique is
likely to overcome this problem as two recent studies have
shown that threading the strings through the cervix at the
time of insertion results in much higher rates of strings
being visible at follow-up.10,11
Expulsion rates may be higher when LNG-IUS is
inserted at CS (0–20%4,9) compared with insertion six
weeks later (3–5%), and larger studies are required to
Table 2 Patient satisfaction at six weeks, three months and six months postpartum following insertion of LNG-IUS at caesarean section
or postpartum
Six weeks Three months Six months
LNG-IUS
Postpartum
(n = 18)
LNG-IUS at
CS (n = 22)
LNG-IUS
Postpartum
(n = 18)
LNG-IUS at
CS (n = 23)
LNG-IUS
Postpartum
(n = 17)
LNG-IUS at
CS
(n = 21)
Very satisfied, % (n) 72.2 (13) 50.0 (11) 61.1 (11) 65.2 (15) 76.5 (13) 66.7 (14)
Somewhat satisfied, % (n) 11.1 (2) 30.9 (9) 22.2 (4) 13.0 (3) 11.8 (2) 23.8 (5)
Neither satisfied/dissatisfied, % (n) 16.7 (3) 9.1 (2) 16.7 (3) 17.4 (4) 0 4.8 (1)
Somewhat dissatisfied, % (n) 0 0 0 0 5.9 (1) 4.8 (1)
Very dissatisfied, % (n) 0 0 0 4.3 (1) 5.9 (1) 0
Mean (SD) 4.56 (0.78) 4.41 (0.67) 4.44 (0.78) 4.35 (1.07) 4.47 (1.18) 4.52 (0.81)
P-value (exact trend test) 0.66 0.87 0.99
Table 3 Visibility of strings, LNG-IUS position and vaginal
bleeding patterns in patients who received LNG-IUS at caesarean
and postpartum
LNG-IUS
postpartum
LNG-IUS
at caesarean P-value
Strings visible, %
Six weeks 100.0 (19/19) 29.2 (7/24) <0.001
Three months 94.4 (17/18) 30.4 (7/23) <0.001
Six months 82.4 (14/17) 31.6 (6/19) 0.003
Correct LNG-IUS position, %
Six weeks 88.9 (16/18) 91.7 (22/24) >0.99
Three months 94.4 (17/18) 91.3 (21/23) >0.99
Six months 88.2 (15/17) 95.2 (20/21) 0.58
Frequent vaginal bleeding, %
Six weeks 10.5 (2/19) 50.0 (12/24) 0.009
Three months 55.6 (10/18) 26.1 (6/23) 0.11
Six months 17.6 (3/17) 9.5 (2/21) 0.64
Table 4 Breastfeeding practices, breastfeeding difficulties and
mean infant weight gain in patients
LNG-IUS
postpartum
LNG-IUS
at caesarean P-value
Breastfeeding, %
Six weeks 36.8 (7/19) 70.8 (17/24) 0.034
Three months 22.2 (4/18) 56.5 (13/23) 0.054
Six months 11.8 (2/17) 52.4 (11/21) 0.015
Breastfeeding difficulties, %
Six weeks 5.3 (1/19) 12.5 (3/24) 0.62
Three months 0 0
Six months 0 0
Mean infant weight gain
Six weeks
Mean (SD)
1496 g (510 g)
n = 15
1399 g (612 g)
n = 20
0.62
Three months
Mean (SD)
2472 g (757 g)
n = 13
2719 g (651 g)
n = 21
0.32
Six months
Mean (SD)
4361 g (792 g)
n = 13
4163 g (1560 g)
n = 14
0.69
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address this issue. In this study, no LNG-IUS was
expelled and there were two LNG-IUS low or oblique
within the uterine cavity in each group. Ultrasound follow-
up to check the position of the LNG-IUS in the cavity
may be prudent regardless of the timing of insertion.
The women who had LNG-IUS inserted at CS were
more likely to breastfeed their babies at six weeks, three
months and six months postpartum (52.4% versus 11.8%
at six months). There were no differences in the rates of
breastfeeding difficulties or infant weight gain. The
difference in breastfeeding rates was unexpected and may
warrant further study, although the current controversial
nature of progestogen-containing contraception in the
neonatal period is acknowledged.18
Insertion of LNG-IUS at CS has a high rate of patient
satisfaction and may have a role for women who desire
effective reversible contraception and who have difficulty
accessing care or who are reluctant to have postnatal
insertion of a contraceptive device.
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